ReviewFrontiers in oncology2020
Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Association of Dietary Diabetes Risk Reduction Score and the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.Nutrients · 2025Pooled it
- Smartphone-Based Physical Activity Program to Reduce "Chemo-Brain" Symptoms and Improve Health in Cancer Survivors With and Without Type 2 Diabetes: Protocol for a Single-Arm Pre-Post Pilot Trial.JMIR research protocols · 2025Article
- Thymoquinone Overcomes Hypoxia-Induced Carboplatin Resistance Through ROS-Independent Apoptosis but Promotes Cancer Stem Cell Enrichment: Implications on Oral Cancer Adaptation and Recurrence.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Advanced Gene-Expression Analysis of Skeletal Muscles Focusing on Normal, Glucose-Intolerant, and Diabetic Individuals with Type 2 Diabetes.Biomedicines · 2025Article
- Association of triglyceride-glucose-related indices with all-cause and cause-specific mortality in individuals with prediabetesss.Cardiovascular diabetology · 2025Article
- Insulin resistance and cancer: molecular links and clinical perspectives.Molecular and cellular biochemistry · 2025Review
- Article
- Short-Term Outcomes of Laparoscopic Sleeve Gastrectomy for Weight Loss and Gastroesophageal Reflux Disease.Cureus · 2025Article
- Diabetes-associated differentially expressed genes as prognostic biomarkers and therapeutic targets in endometrial cancer: a comprehensive molecular analysis.Frontiers in oncology · 2025Article
- Diverse Applications of the Anti-Diabetic Drug Metformin in Treating Human Disease.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Glucose impacts onto the reciprocal reprogramming between mammary adipocytes and cancer cells.Scientific reports · 2024Article
- Exploring the Antidiabetic Potential ofPlants (Basel, Switzerland) · 2024Article
- Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.Molecular biomedicine · 2024Review
- Health Care Use Among Cancer Patients With Diabetes, National Health and Nutrition Examination Survey, 2017-2020.Preventing chronic disease · 2024Article
- Cancer risk following onset of type 2 diabetes in New Zealanders with impaired glucose tolerance over 25 years: a matched prospective cohort study.BMC cancer · 2024Article
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- Systematic review and bioinformatics analysis of plasma and serum extracellular vesicles proteome in type 2 diabetes.Heliyon · 2024Article
- FTO is a major genetic link between breast cancer, obesity, and diabetes.Breast cancer research and treatment · 2024Article
- Applying Network Pharmacology and Molecular Docking in the Screening for Molecular Mechanisms of Ampalaya (Acta medica Philippina · 2024Article
- Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions.Archives of endocrinology and metabolism · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes and cancer are among the most frequent and complex diseases. Epidemiological evidence showed that the patients suffering from diabetes are significantly at higher risk for a number of cancer types. There are a number of evidence that support the hypothesis that these diseases are interlinked, and obesity may aggravate the risk(s) of type 2 diabetes and cancer. Multi-level unwanted alterations such as (epi-)genetic alterations, changes at the transcriptional level, and altered signaling pathways (receptor, cytoplasmic, and nuclear level) are the major source which promotes a number of complex diseases and such heterogeneous level of complexities are considered as the major barrier in the development of therapeutic agents. With so many known challenges, it is critical to understand the relationships and the commonly shared causes between type 2 diabetes and cancer, which is difficult to unravel and understand. Furthermore, the real complexity arises from contended corroborations that specific drug(s) (individually or in combination) during the treatment of type 2 diabetes may increase or decrease the cancer risk or affect cancer prognosis. In this review article, we have presented the recent and most updated evidence from the studies where the origin, biological background, the correlation between them have been presented or proved. Furthermore, we have summarized the methodological challenges and tasks that are frequently encountered. We have also outlined the physiological links between type 2 diabetes and cancers. Finally, we have presented and summarized the outline of the hallmarks for both these diseases, diabetes and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.